Advertisement
Review Article| Volume 34, ISSUE 3, P563-574, September 2014

Management of Anticoagulation Agents in Trauma Patients

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Coimbra R.
        • Hoyt D.B.
        • Anjaria D.J.
        • et al.
        Reversal of anticoagulation in trauma: a North-American survey on clinical practices among trauma surgeons.
        J Trauma. 2005; 59: 375-382
        • Fortuna G.R.
        • Mueller E.W.
        • James L.E.
        • et al.
        The impact of preinjury antiplatelet and anticoagulant pharmacotherapy on outcomes in elderly patients with hemorrhagic brain injury.
        Surgery. 2008; 144 ([discussion: 603–5]): 598-603
        • Kutcher M.E.
        • Ferguson A.R.
        • Cohen M.J.
        A principal component analysis of coagulation after trauma.
        J Trauma Acute Care Surg. 2013; 74 ([discussion: 1229–30]): 1223-1229
        • Romlin B.S.
        • Wahlander H.
        • Synnergren M.
        • et al.
        Earlier detection of coagulopathy with thromboelastometry during pediatric cardiac surgery: a prospective observational study.
        Paediatr Anaesth. 2013; 23: 222-227
        • McCully S.P.
        • Fabricant L.J.
        • Kunio N.R.
        • et al.
        The International Normalized Ratio overestimates coagulopathy in stable trauma and surgical patients.
        J Trauma Acute Care Surg. 2013; 75: 947-953
        • Whiting D.
        • Dinardo J.A.
        TEG and ROTEM: technology and clinical applications.
        Am J Hematol. 2014; 89: 228-232
        • Solomon C.
        • Sorensen B.
        • Hochleitner G.
        • et al.
        Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry.
        Anesth Analg. 2012; 114: 721-730
        • Ahmed N.
        • Kassavin D.
        • Kuo Y.H.
        • et al.
        Sensitivity and specificity of CT scan and angiogram for ongoing internal bleeding following torso trauma.
        Emerg Med J. 2013; 30: e14
        • Roudsari B.
        • Psoter K.J.
        • Fine G.C.
        • et al.
        Falls, older adults, and the trend in utilization of CT in a level I trauma center.
        AJR Am J Roentgenol. 2012; 198: 985-991
        • Prowse S.J.
        • Sloan J.
        NICE guidelines for the investigation of head injuries–an anticoagulant loop hole?.
        Emerg Med J. 2010; 27: 277-278
      1. National Institute for Health and Care Excellence. Head injury clinical guidelines (CG56): triage, assessment, investigation and early management of head injury in infants, children and adults. 2007. Available at: http://www.nice.org.uk/guidance/index.jsp?action=byID&o=11836. Accessed February 10, 2014.

        • Cohen D.B.
        • Rinker C.
        • Wilberger J.E.
        Traumatic brain injury in anticoagulated patients.
        J Trauma. 2006; 60: 553-557
        • Hirsh J.
        • Dalen J.
        • Anderson D.R.
        • et al.
        Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range.
        Chest. 2001; 119: 8S-21S
        • Bonville D.J.
        • Ata A.
        • Jahraus C.B.
        • et al.
        Impact of preinjury warfarin and antiplatelet agents on outcomes of trauma patients.
        Surgery. 2011; 150: 861-868
        • Calland J.F.
        • Ingraham A.M.
        • Martin N.
        • et al.
        Evaluation and management of geriatric trauma: an Eastern Association for the Surgery of Trauma practice management guideline.
        J Trauma Acute Care Surg. 2012; 73: S345-S350
        • Ivascu F.A.
        • Howells G.A.
        • Junn F.S.
        • et al.
        Rapid warfarin reversal in anticoagulated patients with traumatic intracranial hemorrhage reduces hemorrhage progression and mortality.
        J Trauma. 2005; 59 ([discussion: 1137–9]): 1131-1137
        • Ageno W.
        • Garcia D.
        • Aguilar M.I.
        • et al.
        Prevention and treatment of bleeding complications in patients receiving vitamin K antagonists, part 2: treatment.
        Am J Hematol. 2009; 84: 584-588
        • Contreras M.
        • Ala F.A.
        • Greaves M.
        • et al.
        Guidelines for the use of fresh frozen plasma. British Committee for Standards in Haematology, Working Party of the Blood Transfusion Task Force.
        Transfus Med. 1992; 2: 57-63
        • Popovsky M.A.
        Transfusion-related acute lung injury: incidence, pathogenesis and the role of multicomponent apheresis in its prevention.
        Transfus Med Hemother. 2008; 35: 76-79
        • Beshay J.E.
        • Morgan H.
        • Madden C.
        • et al.
        Emergency reversal of anticoagulation and antiplatelet therapies in neurosurgical patients.
        J Neurosurg. 2010; 112: 307-318
        • Sarode R.
        • Matevosyan K.
        • Bhagat R.
        • et al.
        Rapid warfarin reversal: a 3-factor prothrombin complex concentrate and recombinant factor VIIa cocktail for intracerebral hemorrhage.
        J Neurosurg. 2012; 116: 491-497
        • Ageno W.
        • Gallus A.S.
        • Wittkowsky A.
        • et al.
        Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e44S-e88S
      2. CSL Behring GmbH. Kcentra prescribing information. 2013. Available at: http://www.kcentra.com/prescribing-information.aspx. Accessed February 27, 2014.

        • Rosovsky R.P.
        • Crowther M.A.
        What is the evidence for the off-label use of recombinant factor VIIa (rFVIIa) in the acute reversal of warfarin? ASH evidence-based review 2008.
        Hematology Am Soc Hematol Educ Program. 2008; : 36-38https://doi.org/10.1182/asheducation-2008.1.36
        • Lazo-Langner A.
        • Rodger M.A.
        • Wells P.S.
        Lessons from ximelagatran: issues for future studies evaluating new oral direct thrombin inhibitors for venous thromboembolism prophylaxis in orthopedic surgery.
        Clin Appl Thromb Hemost. 2009; 15: 316-326
        • Boudes P.F.
        The challenges of new drugs benefits and risks analysis: lessons from the ximelagatran FDA Cardiovascular Advisory Committee.
        Contemp Clin Trials. 2006; 27: 432-440
        • Nutescu E.A.
        • Shapiro N.L.
        • Chevalier A.
        New anticoagulant agents: direct thrombin inhibitors.
        Cardiol Clin. 2008; 26 (v–vi): 169-187
        • Blech S.
        • Ebner T.
        • Ludwig-Schwellinger E.
        • et al.
        The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans.
        Drug Metab Dispos. 2008; 36: 386-399
        • Wienen W.
        • Stassen J.M.
        • Priepke H.
        • et al.
        In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
        Thromb Haemost. 2007; 98: 155-162
        • Lange U.
        • Nowak G.
        • Bucha E.
        Ecarin chromogenic assay–a new method for quantitative determination of direct thrombin inhibitors like hirudin.
        Pathophysiol Haemost Thromb. 2003; 33: 184-191
        • Engstrom M.
        • Rundgren M.
        • Schott U.
        An evaluation of monitoring possibilities of argatroban using rotational thromboelastometry and activated partial thromboplastin time.
        Acta Anaesthesiol Scand. 2010; 54: 86-91
        • van Ryn J.
        • Stangier J.
        • Haertter S.
        • et al.
        Dabigatran etexilate–a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
        Thromb Haemost. 2010; 103: 1116-1127
      3. Boehringer Ingelheim Pharmaceuticals. Pradaxa prescribing information. 2013. Available at: http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf. Accessed February 27, 2014.

        • Crowther M.A.
        • Warkentin T.E.
        Managing bleeding in anticoagulated patients with a focus on novel therapeutic agents.
        J Thromb Haemost. 2009; 7: 107-110
        • Garber S.T.
        • Sivakumar W.
        • Schmidt R.H.
        Neurosurgical complications of direct thrombin inhibitors–catastrophic hemorrhage after mild traumatic brain injury in a patient receiving dabigatran.
        J Neurosurg. 2012; 116: 1093-1096
        • Gruber A.
        • Carlsson S.
        • Kotze H.F.
        • et al.
        Hemostatic effect of activated factor VII without promotion of thrombus growth in melagatran-anticoagulated primates.
        Thromb Res. 2007; 119: 121-127
        • Oh J.J.
        • Akers W.S.
        • Lewis D.
        • et al.
        Recombinant factor VIIa for refractory bleeding after cardiac surgery secondary to anticoagulation with the direct thrombin inhibitor lepirudin.
        Pharmacotherapy. 2006; 26: 569-577
        • Wolzt M.
        • Levi M.
        • Sarich T.C.
        • et al.
        Effect of recombinant factor VIIa on melagatran-induced inhibition of thrombin generation and platelet activation in healthy volunteers.
        Thromb Haemost. 2004; 91: 1090-1096
        • Faust A.C.
        • Peterson E.J.
        Management of dabigatran-associated intracerebral and intraventricular hemorrhage: a case report.
        J Emerg Med. 2014; 46: 525-529https://doi.org/10.1016/j.jemermed.2013.11.097
        • Dumkow L.E.
        • Voss J.R.
        • Peters M.
        • et al.
        Reversal of dabigatran-induced bleeding with a prothrombin complex concentrate and fresh frozen plasma.
        Am J Health Syst Pharm. 2012; 69: 1646-1650
        • Schiele F.
        • van Ryn J.
        • Canada K.
        • et al.
        A specific antidote for dabigatran: functional and structural characterization.
        Blood. 2013; 121: 3554-3562
        • Perzborn E.
        • Roehrig S.
        • Straub A.
        • et al.
        Rivaroxaban: a new oral factor Xa inhibitor.
        Arterioscler Thromb Vasc Biol. 2010; 30: 376-381
        • Gerotziafas G.T.
        • Elalamy I.
        • Depasse F.
        • et al.
        In vitro inhibition of thrombin generation, after tissue factor pathway activation, by the oral, direct factor Xa inhibitor rivaroxaban.
        J Thromb Haemost. 2007; 5: 886-888
        • Kakkar A.K.
        • Brenner B.
        • Dahl O.E.
        • et al.
        Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial.
        Lancet. 2008; 372: 31-39
        • Eriksson B.I.
        • Borris L.C.
        • Friedman R.J.
        • et al.
        Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.
        N Engl J Med. 2008; 358: 2765-2775
        • Samama M.M.
        • Martinoli J.L.
        • LeFlem L.
        • et al.
        Assessment of laboratory assays to measure rivaroxaban–an oral, direct factor Xa inhibitor.
        Thromb Haemost. 2010; 103: 815-825
        • Martin A.C.
        • Le Bonniec B.
        • Fischer A.M.
        • et al.
        Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis.
        Int J Cardiol. 2013; 168: 4228-4233
        • Escolar G.
        • Fernandez-Gallego V.
        • Arellano-Rodrigo E.
        • et al.
        Reversal of apixaban induced alterations in hemostasis by different coagulation factor concentrates: significance of studies in vitro with circulating human blood.
        PLoS One. 2013; 8: e78696
        • Perzborn E.
        • Gruber A.
        • Tinel H.
        • et al.
        Reversal of rivaroxaban anticoagulation by haemostatic agents in rats and primates.
        Thromb Haemost. 2013; 110: 162-172
        • Garcia D.A.
        • Baglin T.P.
        • Weitz J.I.
        • et al.
        Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines.
        Chest. 2012; 141: e24S-e43S
        • Abbate R.
        • Gori A.M.
        • Farsi A.
        • et al.
        Monitoring of low-molecular-weight heparins in cardiovascular disease.
        Am J Cardiol. 1998; 82: 33L-36L
        • Mittermayr M.
        • Velik-Salchner C.
        • Stalzer B.
        • et al.
        Detection of protamine and heparin after termination of cardiopulmonary bypass by thrombelastometry (ROTEM): results of a pilot study.
        Anesth Analg. 2009; 108: 743-750
        • Pai M.
        • Crowther M.A.
        Neutralization of heparin activity.
        Handb Exp Pharmacol. 2012; : 265-277
        • Young G.
        • Yonekawa K.E.
        • Nakagawa P.A.
        • et al.
        Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
        Blood Coagul Fibrinolysis. 2007; 18: 547-553
        • Doyal L.
        • Wilsher D.
        Towards guidelines for withholding and withdrawal of life prolonging treatment in neonatal medicine.
        Arch Dis Child Fetal Neonatal Ed. 1994; 70: F66-F70
        • Yusuf S.
        • Zhao F.
        • Mehta S.R.
        • et al.
        Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
        N Engl J Med. 2001; 345: 494-502
        • Campbell P.G.
        • Sen A.
        • Yadla S.
        • et al.
        Emergency reversal of antiplatelet agents in patients presenting with an intracranial hemorrhage: a clinical review.
        World Neurosurg. 2010; 74: 279-285
        • Ohm C.
        • Mina A.
        • Howells G.
        • et al.
        Effects of antiplatelet agents on outcomes for elderly patients with traumatic intracranial hemorrhage.
        J Trauma. 2005; 58: 518-522
        • Harder S.
        • Klinkhardt U.
        • Alvarez J.M.
        Avoidance of bleeding during surgery in patients receiving anticoagulant and/or antiplatelet therapy: pharmacokinetic and pharmacodynamic considerations.
        Clin Pharmacokinet. 2004; 43: 963-981
        • Grove E.L.
        • Hvas A.M.
        • Johnsen H.L.
        • et al.
        A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.
        Thromb Haemost. 2010; 103: 1245-1253
        • Joseph B.
        • Pandit V.
        • Sadoun M.
        • et al.
        A prospective evaluation of platelet function in patients on antiplatelet therapy with traumatic intracranial hemorrhage.
        J Trauma Acute Care Surg. 2013; 75: 990-994
        • Murugappa S.
        • Kunapuli S.P.
        The role of ADP receptors in platelet function.
        Front Biosci. 2006; 11: 1977-1986
        • Swallow R.A.
        • Agarwala R.A.
        • Dawkins K.D.
        • et al.
        Thromboelastography: potential bedside tool to assess the effects of antiplatelet therapy?.
        Platelets. 2006; 17: 385-392
        • Collyer T.C.
        • Gray D.J.
        • Sandhu R.
        • et al.
        Assessment of platelet inhibition secondary to clopidogrel and aspirin therapy in preoperative acute surgical patients measured by thrombelastography platelet mapping.
        Br J Anaesth. 2009; 102: 492-498
        • Taylor G.
        • Osinski D.
        • Thevenin A.
        • et al.
        Is platelet transfusion efficient to restore platelet reactivity in patients who are responders to aspirin and/or clopidogrel before emergency surgery?.
        J Trauma Acute Care Surg. 2013; 74: 1367-1369
        • Nishijima D.K.
        • Zehtabchi S.
        • Berrong J.
        • et al.
        Utility of platelet transfusion in adult patients with traumatic intracranial hemorrhage and preinjury antiplatelet use: a systematic review.
        J Trauma Acute Care Surg. 2012; 72: 1658-1663